N
Nimbus Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2009
Applying deep computational chemistry expertise to create novel small molecule therapeutics MoreLess
Nimbus Therapeutics is a biotechnology company focused on designing small molecule therapeutics to address significant challenges in drug development. The company operates in the pharmaceutical and biotechnology market, serving patients with unmet medical needs. Nimbus employs a unique collective expertise to push the boundaries of drug discovery and development. The business model revolves around research and development of breakthrough medicines, backed by substantial investments from prominent life science investors like Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, and Lightstone Ventures. Nimbus generates revenue through partnerships, licensing agreements, and milestone payments from pharmaceutical companies. The company has secured multiple rounds of financing, including a $24 million Series A in 2011, a $43 million Series B in 2015, and an additional $65 million in 2018.
Keywords: small molecule therapeutics, drug discovery, biotechnology, pharmaceutical, life science investors, breakthrough medicines, research and development, licensing agreements, milestone payments, unmet medical needs.
Company overview
Nimbus Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2009
- Headquarters
- Cambridge, United States
- Employees
- 101
- Open positions
- None listed
- Dealroom signal
- 38.8
Valuation & funding
Nimbus Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Sep 2023 | $210M | $840M | Atlas Venture · Lightstone Ventures · RA Capital Management · Pfizer Ventures | ↗ |
| ACQUISITIONOther financing | Dec 2022 | $0 | — | Takeda | ↗ |
| LATE VCOther financing | Sep 2022 | $125M | $500M | BVF Partners · SV Health Investors · Pfizer Ventures · Access Biotechnology | ↗ |
| LATE VCOther financing | Jul 2021 | $105M | $420M | Commodore Capital · Atlas Venture · RA Capital Management · Logos Capital | — |
| LATE VCOther financing | Oct 2020 | $60M | $240M | Undisclosed | — |
| SERIES COther financing | Jun 2018 | Pfizer Ventures · SR One | — | ||
| SERIES BOther financing | Mar 2015 | Pfizer Ventures · Atlas Venture · Bill Gates · SR One | — | ||
| SERIES AOther financing | Jun 2011 | SR One · Lilly Ventures · Bill Gates · Atlas Venture | — | ||
| SEEDOther financing | Mar 2011 | Atlas Venture · Bill Gates · Richard Friesner | — | ||
| EARLY VCOther financing | Apr 2010 | Pfizer Ventures | — |
Growth signals
Nimbus Therapeutics website traffic
Latest recorded traffic for Nimbus Therapeutics is 12K monthly website visits, up 20% over the last three months. Nimbus Therapeutics's team grew 3.1% over the past year.
Comparisons
Nimbus Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Nimbus Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
18 investors on Nimbus Therapeutics's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Nimbus Therapeutics has talent and traffic
team presence
In the news
Latest news about Nimbus Therapeutics
Recent press, funding announcements, and product moves mentioning Nimbus Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Nimbus Therapeutics
An AI-synthesized read of the highest-engagement posts about Nimbus Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nimbus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.